CorMedix Operating Income vs Other Operating Expenses Analysis

CRMD Stock

USD 9.96 0.37 3.58%

CorMedix financial indicator trend analysis is way more than just evaluating CorMedix prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CorMedix is a good investment. Please check the relationship between CorMedix Operating Income and its Other Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.

Operating Income vs Other Operating Expenses

Operating Income vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CorMedix Operating Income account and Other Operating Expenses. At this time, the significance of the direction appears to have pay attention.

The correlation between CorMedix's Operating Income and Other Operating Expenses is -1.0. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of CorMedix, assuming nothing else is changed. The correlation between historical values of CorMedix's Operating Income and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of CorMedix are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Operating Income i.e., CorMedix's Operating Income and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

-1.0

Relationship Direction	Negative
Relationship Strength	Strong

View All Relationships

Operating Income

Operating Income is the amount of profit realized from CorMedix operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CorMedix is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CorMedix. It is also known as CorMedix overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from CorMedix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CorMedix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.At present, CorMedix's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 155.8 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 20.53.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	177.0K	209.0K	70.8K	79.6K
Research Development	13.1M	10.7M	13.2M	10.2M

Depreciation And Amortization Research Development

CorMedix fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Assets	Other Current Assets	Total Liab	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Other Liab	Non Current Liabilities Total
Total Assets		0.75	0.48	0.81	0.94	0.2	0.61	0.24	0.26	0.92	-0.52	-0.14	0.93	-0.93	-0.93	0.91	-0.15	1.0	0.21	0.96	0.93	0.93	1.0	-0.28	-0.26	-0.15
Other Current Liab	0.75		0.68	0.85	0.68	0.28	0.41	0.55	0.61	0.72	-0.34	-0.16	0.66	-0.64	-0.88	0.64	0.05	0.74	0.56	0.84	0.54	0.67	0.75	-0.22	-0.26	0.09
Total Current Liabilities	0.48	0.68		0.62	0.41	0.08	0.08	0.82	0.24	0.54	0.23	0.06	0.48	-0.26	-0.49	0.55	0.38	0.47	0.19	0.53	0.36	0.49	0.48	0.55	-0.28	-0.04
Accounts Payable	0.81	0.85	0.62		0.68	-0.09	0.39	0.43	0.5	0.83	-0.32	0.19	0.77	-0.64	-0.8	0.75	0.15	0.8	0.44	0.82	0.73	0.79	0.81	-0.24	-0.21	0.06
Cash	0.94	0.68	0.41	0.68		0.42	0.6	0.26	0.3	0.88	-0.54	-0.4	0.94	-0.98	-0.92	0.92	-0.27	0.95	0.26	0.94	0.88	0.92	0.94	-0.27	-0.25	-0.05
Other Assets	0.2	0.28	0.08	-0.09	0.42		0.24	0.29	0.34	0.06	-0.23	-0.82	0.14	-0.38	-0.37	0.13	-0.32	0.22	0.36	0.3	0.01	0.11	0.21	-0.08	-0.19	0.31
Other Current Assets	0.61	0.41	0.08	0.39	0.6	0.24		0.06	0.36	0.42	-0.28	-0.16	0.43	-0.64	-0.59	0.39	-0.59	0.61	0.33	0.5	0.58	0.41	0.62	-0.39	-0.13	-0.04
Total Liab	0.24	0.55	0.82	0.43	0.26	0.29	0.06		0.46	0.3	0.38	-0.12	0.27	-0.12	-0.34	0.33	0.35	0.24	0.42	0.33	0.1	0.27	0.24	0.49	0.04	0.46
Common Stock	0.26	0.61	0.24	0.5	0.3	0.34	0.36	0.46		0.18	-0.01	-0.34	0.18	-0.3	-0.48	0.13	-0.02	0.26	0.99	0.33	0.07	0.17	0.27	-0.37	-0.21	0.47
Property Plant Equipment	0.92	0.72	0.54	0.83	0.88	0.06	0.42	0.3	0.18		-0.5	-0.07	0.97	-0.85	-0.89	0.97	-0.06	0.92	0.11	0.95	0.94	0.98	0.92	-0.18	-0.18	-0.12
Short Long Term Debt Total	-0.52	-0.34	0.23	-0.32	-0.54	-0.23	-0.28	0.38	-0.01	-0.5		0.22	-0.51	0.64	0.55	-0.44	0.37	-0.52	0.01	-0.58	-0.5	-0.51	-0.52	0.7	0.17	0.17
Total Stockholder Equity	-0.14	-0.16	0.06	0.19	-0.4	-0.82	-0.16	-0.12	-0.34	-0.07	0.22		-0.19	0.4	0.33	-0.17	0.27	-0.16	-0.36	-0.23	0.0	-0.16	-0.14	0.14	0.15	-0.16
Property Plant And Equipment Net	0.93	0.66	0.48	0.77	0.94	0.14	0.43	0.27	0.18	0.97	-0.51	-0.19		-0.91	-0.88	0.99	-0.06	0.93	0.11	0.94	0.94	1.0	0.93	-0.19	-0.19	-0.11
Net Debt	-0.93	-0.64	-0.26	-0.64	-0.98	-0.38	-0.64	-0.12	-0.3	-0.85	0.64	0.4	-0.91		0.92	-0.87	0.34	-0.93	-0.25	-0.92	-0.88	-0.9	-0.93	0.42	0.22	0.07
Retained Earnings	-0.93	-0.88	-0.49	-0.8	-0.92	-0.37	-0.59	-0.34	-0.48	-0.89	0.55	0.33	-0.88	0.92		-0.85	0.16	-0.93	-0.42	-0.98	-0.81	-0.88	-0.93	0.36	0.28	0.02
Non Current Assets Total	0.91	0.64	0.55	0.75	0.92	0.13	0.39	0.33	0.13	0.97	-0.44	-0.17	0.99	-0.87	-0.85		0.0	0.91	0.07	0.92	0.93	0.99	0.91	-0.07	-0.2	-0.13
Non Currrent Assets Other	-0.15	0.05	0.38	0.15	-0.27	-0.32	-0.59	0.35	-0.02	-0.06	0.37	0.27	-0.06	0.34	0.16	0.0		-0.15	-0.04	-0.11	-0.22	-0.02	-0.15	0.4	0.0	0.02
Cash And Short Term Investments	1.0	0.74	0.47	0.8	0.95	0.22	0.61	0.24	0.26	0.92	-0.52	-0.16	0.93	-0.93	-0.93	0.91	-0.15		0.21	0.96	0.93	0.93	1.0	-0.27	-0.27	-0.15
Common Stock Total Equity	0.21	0.56	0.19	0.44	0.26	0.36	0.33	0.42	0.99	0.11	0.01	-0.36	0.11	-0.25	-0.42	0.07	-0.04	0.21		0.27	0.01	0.11	0.21	-0.38	-0.2	0.49
Common Stock Shares Outstanding	0.96	0.84	0.53	0.82	0.94	0.3	0.5	0.33	0.33	0.95	-0.58	-0.23	0.94	-0.92	-0.98	0.92	-0.11	0.96	0.27		0.87	0.94	0.95	-0.28	-0.24	-0.06
Other Stockholder Equity	0.93	0.54	0.36	0.73	0.88	0.01	0.58	0.1	0.07	0.94	-0.5	0.0	0.94	-0.88	-0.81	0.93	-0.22	0.93	0.01	0.87		0.94	0.93	-0.24	-0.17	-0.19
Property Plant And Equipment Gross	0.93	0.67	0.49	0.79	0.92	0.11	0.41	0.27	0.17	0.98	-0.51	-0.16	1.0	-0.9	-0.88	0.99	-0.02	0.93	0.11	0.94	0.94		0.93	-0.18	-0.18	-0.12
Total Current Assets	1.0	0.75	0.48	0.81	0.94	0.21	0.62	0.24	0.27	0.92	-0.52	-0.14	0.93	-0.93	-0.93	0.91	-0.15	1.0	0.21	0.95	0.93	0.93		-0.28	-0.27	-0.15
Short Term Debt	-0.28	-0.22	0.55	-0.24	-0.27	-0.08	-0.39	0.49	-0.37	-0.18	0.7	0.14	-0.19	0.42	0.36	-0.07	0.4	-0.27	-0.38	-0.28	-0.24	-0.18	-0.28		-0.08	-0.15
Other Liab	-0.26	-0.26	-0.28	-0.21	-0.25	-0.19	-0.13	0.04	-0.21	-0.18	0.17	0.15	-0.19	0.22	0.28	-0.2	0.0	-0.27	-0.2	-0.24	-0.17	-0.18	-0.27	-0.08		0.61
Non Current Liabilities Total	-0.15	0.09	-0.04	0.06	-0.05	0.31	-0.04	0.46	0.47	-0.12	0.17	-0.16	-0.11	0.07	0.02	-0.13	0.02	-0.15	0.49	-0.06	-0.19	-0.12	-0.15	-0.15	0.61

Click cells to compare fundamentals

CorMedix Account Relationship Matchups

CorMedix fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	29.5M	49.3M	68.9M	62.0M	82.1M	86.2M
Other Current Liab	4.8M	2.9M	3.0M	4.0M	7.0M	7.3M
Total Current Liabilities	5.8M	4.2M	5.3M	6.3M	11.4M	12.0M
Accounts Payable	1.0M	1.1M	2.2M	2.2M	4.3M	4.5M
Cash	16.5M	42.1M	53.6M	43.4M	43.6M	45.8M
Other Current Assets	501.2K	1.7M	954.0K	758.8K	1.3M	725.0K
Total Liab	5.8M	5.1M	6.1M	7.0M	11.9M	7.3M
Common Stock	25.7K	33.6K	38.1K	42.8K	54.9K	36.3K
Property Plant Equipment	126.8K	1.1M	1.5M	2.4M	2.7M	2.9M
Short Long Term Debt Total	2.7K	1.0M	923.8K	802.4K	667.6K	634.3K
Total Stockholder Equity	(195.4M)	(217.4M)	(245.7M)	(275.4M)	70.1M	73.6M
Property Plant And Equipment Net	126.8K	1.1M	2.4M	2.4M	2.5M	2.6M
Net Debt	(16.5M)	(41.1M)	(52.6M)	(42.6M)	(43.0M)	(40.8M)
Retained Earnings	(195.4M)	(217.4M)	(245.7M)	(275.4M)	(321.7M)	(305.6M)
Non Current Assets Total	126.8K	1.1M	2.5M	2.5M	2.6M	2.7M
Non Currrent Assets Other	126.8K	(1.1M)	102.3K	102.3K	103.1K	108.2K
Cash And Short Term Investments	28.5M	46.5M	65.7M	59.0M	76.0M	79.8M
Common Stock Total Equity	108.9K	25.7K	33.6K	38.1K	43.8K	36.2K
Common Stock Shares Outstanding	24.2M	28.6M	37.7M	40.3M	50.9M	53.4M
Liabilities And Stockholders Equity	(189.6M)	(212.4M)	(239.5M)	(268.4M)	82.1M	86.2M
Other Stockholder Equity	(123.2K)	261.5M	308.3M	330.3M	391.7M	411.3M
Property Plant And Equipment Gross	126.8K	1.1M	2.7M	2.8M	3.0M	3.2M
Total Current Assets	29.3M	48.2M	66.5M	59.6M	79.5M	83.4M
Accumulated Other Comprehensive Income	97.3K	102.0K	87.1K	82.7K	94.1K	56.5K
Non Current Liabilities Total	2.7K	923.7K	802.4K	667.6K	517.0K	491.2K
Net Tangible Assets	23.6M	44.2M	62.8M	55.1M	63.3M	66.5M
Net Receivables	64.1K	10.9K	35.0	3.4K	45.4K	0.0
Retained Earnings Total Equity	(179.0M)	(195.4M)	(217.4M)	(245.7M)	(221.1M)	(210.0M)
Short Term Investments	12.0M	4.4M	12.1M	15.6M	32.4M	34.0M
Capital Surpluse	183.7M	218.9M	261.5M	308.3M	354.6M	372.3M
Inventory	428.5K	338.5K	143.6K	3.0K	2.1M	2.2M
Net Invested Capital	23.6M	44.2M	62.8M	55.1M	70.1M	43.1M
Net Working Capital	23.5M	44.0M	61.1M	53.2M	68.0M	42.1M
Capital Stock	25.9K	33.8K	38.3K	43.0K	55.1K	40.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:

How To Invest In CorMedix

Details

Is CorMedix Stock a good investment?

Details

What is CorMedix's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.80)

Revenue Per Share

0.212

Quarterly Revenue Growth

(0.47)

Return On Assets

(0.38)

Return On Equity

(0.65)

The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CorMedix Operating Income vs Other Operating Expenses Analysis

Operating Income vs Other Operating Expenses

Operating Income vs Other Operating Expenses Correlation Analysis

Correlation Coefficient

Operating Income

Other Operating Expenses

CorMedix fundamental ratios Correlations

CorMedix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CorMedix fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Total Equity	+ 0.99	Common Stock
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Net Debt	- 0.98	Cash
Total Current Assets	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.93	Retained Earnings
Total Current Assets	- 0.93	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt